Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study
Open Access
- 1 September 2002
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (9), 3204-3208
- https://doi.org/10.1128/jcm.40.9.3204-3208.2002
Abstract
Standard conditions are not available for evaluating the minimum fungicidal concentrations (MFCs) of antifungal agents. This multicenter collaborative study investigated the reproducibility in three laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B MFCs for 15 selected isolates of Aspergillus spp. After MIC determinations for the 15 isolates in each center by the NCCLS M38-A broth microdilution method with four media, standard RPMI 1640 (RPMI), RPMI with 2% dextrose, antibiotic medium 3 (M3), and M3 with 2% dextrose, MFCs were determined for each isolate-medium-drug combination. MFCs were defined as the lowest drug dilutions that yielded Aspergillus spp. and warrant consideration for introduction into future versions of the M38 document. The role of the MFC under these standardized testing conditions as a predictor of clinical outcome needs to be established in clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Optimal Susceptibility Testing Conditions for Detection of Azole Resistance in Aspergillus spp.: NCCLS Collaborative EvaluationAntimicrobial Agents and Chemotherapy, 2001
- Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan AntigenemiaAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous FungiJournal of Clinical Microbiology, 2001
- In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literatureMycopathologia, 2001
- In vitro efficacy and fungicidal activity of voriconazole againstAspergillus andFusarium speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients withCandidaFungemiaThe Journal of Infectious Diseases, 1998
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996
- Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungiAntimicrobial Agents and Chemotherapy, 1995
- Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasmaAntimicrobial Agents and Chemotherapy, 1994
- Efficacy of Unilamellar Liposomal Amphotericin B in Treatment of Pulmonary Aspergillosis in Persistently Granulocytopenic Rabbits: The Potential Role of Bronchoalveolar D-Mannitol and Serum Galactomannan as Markers of InfectionThe Journal of Infectious Diseases, 1994